{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T16:29:49Z","timestamp":1763224189732},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T00:00:00Z","timestamp":1584576000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T00:00:00Z","timestamp":1584576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Positron emission tomography (PET) imaging is used to localize recurrent disease in prostate cancer (PCa). The tracer <jats:sup>68<\/jats:sup>Ga-PSMA-11 visualizes lesions overexpressing prostate-specific membrane antigen (PSMA), while <jats:sup>11<\/jats:sup>C-acetate visualizes lesions with increased anabolic metabolism. The aim of this study was to compare the performance of PSMA-PET and acetate-PET in re-staging patients with biochemical relapse. Thirty PCa patients with prostate-specific antigen (PSA) relapse after primary curative therapy were prospectively evaluated. PET\/CT examinations using <jats:sup>11<\/jats:sup>C-acetate and <jats:sup>68<\/jats:sup>Ga-PSMA-11 were performed. Identified lesions were categorized according to anatomical location and PET measurements were correlated with PSA at time of scan. Tumour lesions showed higher semi-quantitative uptake values on PSMA-PET than acetate-PET. PSMA-PET identified more lesions in 11 patients, fewer lesions in eight patients, and identical number of lesions in 11 patients. This study indicates better diagnostic performance of PSMA-PET, particularly in detecting lymph node (81% vs 60%, p\u2009=\u20090.02) and bone metastasis (95% vs 61%, p\u2009=\u20090.0001) compared to acetate-PET. However, 38% of PSMA-expressing metastases appear to be metabolically inactive and 15% of metabolically active metastases lack PSMA expression. Addition of PET with a metabolic tracer, such as <jats:sup>11<\/jats:sup>C-acetate, might be beneficial before making treatment decisions.<\/jats:p>","DOI":"10.1038\/s41598-020-61910-6","type":"journal-article","created":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T11:04:07Z","timestamp":1584615847000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Comparison of 68Ga-PSMA-11 PET\/CT with 11C-acetate PET\/CT in re-staging of prostate cancer relapse"],"prefix":"10.1038","volume":"10","author":[{"given":"Naresh","family":"Regula","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasileios","family":"Kostaras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Trampal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elin","family":"Lindstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Lubberink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Velikyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"S\u00f6rensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,19]]},"reference":[{"key":"61910_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394\u2013424 (2018).","journal-title":"CA Cancer J. Clin."},{"key":"61910_CR2","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/sj.pcan.4500732","volume":"7","author":"SRJ Bott","year":"2004","unstructured":"Bott, S. R. J. Management of recurrent disease after radical prostatectomy. Prostate Cancer And Prostatic Diseases. 7, 211\u2013216 (2004).","journal-title":"Prostate Cancer And Prostatic Diseases."},{"key":"61910_CR3","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","volume":"71","author":"P Cornford","year":"2017","unstructured":"Cornford, P. et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. Eur. Urol. 71, 630\u2013642 (2017).","journal-title":"Eur. Urol."},{"key":"61910_CR4","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","volume":"71","author":"N Mottet","year":"2017","unstructured":"Mottet, N. et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur. Urol. 71, 618\u2013629 (2017).","journal-title":"Eur. Urol."},{"key":"61910_CR5","doi-asserted-by":"publisher","first-page":"921674","DOI":"10.1155\/2012\/921674","volume":"2012","author":"S Kosuri","year":"2012","unstructured":"Kosuri, S., Akhtar, N. H., Smith, M., Osborne, J. R. & Tagawa, S. T. Review of salvage therapy for biochemically recurrent prostate cancer: the role of imaging and rationale for systemic salvage targeted anti-prostate-specific membrane antigen radioimmunotherapy. Adv. Urol. 2012, 921674\u2013921674 (2012).","journal-title":"Adv. Urol."},{"key":"61910_CR6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.clon.2009.10.015","volume":"22","author":"MJ Beresford","year":"2010","unstructured":"Beresford, M. J., Gillatt, D., Benson, R. J. & Ajithkumar, T. A Systematic Review of the Role of Imaging before Salvage Radiotherapy for Post-prostatectomy Biochemical Recurrence. Clin. Oncol. 22, 46\u201355 (2010).","journal-title":"Clin. Oncol."},{"key":"61910_CR7","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S1470-2045(10)70103-0","volume":"12","author":"AJ Beer","year":"2011","unstructured":"Beer, A. J., Eiber, M., Souvatzoglou, M., Schwaiger, M. & Krause, B. J. Radionuclide and hybrid imaging of recurrent prostate cancer. Lancet Oncol. 12, 181\u2013191 (2011).","journal-title":"Lancet Oncol."},{"key":"61910_CR8","doi-asserted-by":"publisher","first-page":"951","DOI":"10.2174\/1568026611313080008","volume":"13","author":"RC Mease","year":"2013","unstructured":"Mease, R. C., Foss, C. A. & Pomper, M. G. PET Imaging in Prostate Cancer: Focus on Prostate-Specific Membrane Antigen. Curr. Top. Med. Chem. 13, 951\u2013962 (2013).","journal-title":"Curr. Top. Med. Chem."},{"key":"61910_CR9","first-page":"367","volume":"56","author":"P Castellucci","year":"2012","unstructured":"Castellucci, P. & Jadvar, H. PET\/CT in prostate cancer: non-choline radiopharmaceuticals. Q. J. nucl. Med. Mol. Imaging. 56, 367\u2013374 (2012).","journal-title":"Q. J. nucl. Med. Mol. Imaging."},{"key":"61910_CR10","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s00259-007-0581-4","volume":"35","author":"BJ Krause","year":"2008","unstructured":"Krause, B. J. et al. The detection rate of [11C]choline-PET\/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur. J. Nucl. Med. Mol. Imaging. 35, 18\u201323 (2008).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging."},{"key":"61910_CR11","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1111\/bju.12279","volume":"112","author":"B Mohsen","year":"2013","unstructured":"Mohsen, B. et al. Application of C-11-acetate positron-emission tomography (PET) imaging in prostate cancer: systematic review and meta-analysis of the literature. BJU Int. 112, 1062\u20131072 (2013).","journal-title":"BJU Int."},{"key":"61910_CR12","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s00259-009-1253-3","volume":"37","author":"G Giovacchini","year":"2010","unstructured":"Giovacchini, G. et al. Predictive factors of [(11)C]choline PET\/CT in patients with biochemical failure after radical prostatectomy. Eur. J. Nucl. Med. Mol. Imaging. 37, 301\u2013309 (2010).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging."},{"key":"61910_CR13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1055\/s-0038-1623902","volume":"42","author":"J Kotzerke","year":"2003","unstructured":"Kotzerke, J. et al. Intraindividual comparison of [11C]acetate and [11C]choline PET for detection of metastases of prostate cancer. Nuklearmedizin. 42, 25\u201330 (2003).","journal-title":"Nuklearmedizin."},{"key":"61910_CR14","doi-asserted-by":"publisher","first-page":"e64570","DOI":"10.1371\/journal.pone.0064570","volume":"8","author":"Y Yoshii","year":"2013","unstructured":"Yoshii, Y. et al. Fatty acid synthase is a key target in multiple essential tumor functions of prostate cancer: uptake of radiolabeled acetate as a predictor of the targeted therapy outcome. PLoS one. 8, e64570 (2013).","journal-title":"PLoS one."},{"key":"61910_CR15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0969-8051(00)00195-5","volume":"28","author":"M Yoshimoto","year":"2001","unstructured":"Yoshimoto, M. et al. Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. Nucl. Med. Biol. 28, 117\u2013122 (2001).","journal-title":"Nucl. Med. Biol."},{"key":"61910_CR16","first-page":"549","volume":"44","author":"N Oyama","year":"2003","unstructured":"Oyama, N. et al. 11C-Acetate PET Imaging of Prostate Cancer: Detection of Recurrent Disease at PSA Relapse. J. Nucl. Med. 44, 549\u2013555 (2003).","journal-title":"J. Nucl. Med."},{"key":"61910_CR17","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1002\/pros.23061","volume":"75","author":"A Leisser","year":"2015","unstructured":"Leisser, A. et al. Evaluation of fatty acid synthase in prostate cancer recurrence: SUV of [(11) C]acetate PET as a prognostic marker. Prostate. 75, 1760\u20131767 (2015).","journal-title":"Prostate."},{"key":"61910_CR18","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1007\/s00259-016-3449-7","volume":"43","author":"N Regula","year":"2016","unstructured":"Regula, N., H\u00e4ggman, M., Johansson, S. & S\u00f6rensen, J. Malignant lipogenesis defined by 11C-acetate PET\/CT predicts prostate cancer-specific survival in patients with biochemical relapse after prostatectomy. Eur. J. Nucl. Med. Mol. Imaging. 43, 2131\u20132138 (2016).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging."},{"key":"61910_CR19","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/jcb.10661","volume":"91","author":"A Ghosh","year":"2004","unstructured":"Ghosh, A. & Heston, W. D. W. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J. Cell Biochem. 91, 528\u2013539 (2004).","journal-title":"J. Cell Biochem."},{"key":"61910_CR20","doi-asserted-by":"publisher","first-page":"6932","DOI":"10.1158\/0008-5472.CAN-09-1682","volume":"69","author":"SM Hillier","year":"2009","unstructured":"Hillier, S. M. et al. Preclinical Evaluation of Novel Glutamate-Urea-Lysine Analogues That Target Prostate-Specific Membrane Antigen as Molecular Imaging Pharmaceuticals for Prostate Cancer. Cancer Res. 69, 6932\u20136940 (2009).","journal-title":"Cancer Res."},{"key":"61910_CR21","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1021\/bc200279b","volume":"23","author":"M Eder","year":"2012","unstructured":"Eder, M. et al. 68Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging. Bioconjug Chem. 23, 688\u2013697 (2012).","journal-title":"Bioconjug Chem."},{"key":"61910_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/2191-219X-2-23","volume":"2","author":"M Sch\u00e4fer","year":"2012","unstructured":"Sch\u00e4fer, M. et al. A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer. EJNMMI Res. 2, 23 (2012).","journal-title":"EJNMMI Res."},{"key":"61910_CR23","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0090-4295(98)00278-7","volume":"52","author":"SD Sweat","year":"1998","unstructured":"Sweat, S. D., Pacelli, A., Murphy, G. P. & Bostwick, D. G. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology. 52, 637\u2013640 (1998).","journal-title":"Urology."},{"issue":"Suppl 10","key":"61910_CR24","first-page":"S13","volume":"6","author":"SS Chang","year":"2004","unstructured":"Chang, S. S. Overview of prostate-specific membrane antigen. Rev. Urol. 6(Suppl 10), S13\u2013S18 (2004).","journal-title":"Rev. Urol."},{"key":"61910_CR25","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s12253-008-9104-2","volume":"15","author":"S Mannweiler","year":"2009","unstructured":"Mannweiler, S. et al. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol. Oncol. Res. 15, 167\u2013172 (2009).","journal-title":"Pathol. Oncol. Res."},{"key":"61910_CR26","first-page":"81","volume":"3","author":"DA Silver","year":"1997","unstructured":"Silver, D. A., Pellicer, I., Fair, W. R., Heston, W. D. & Cordon-Cardo, C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res. 3, 81\u201385 (1997).","journal-title":"Clin. Cancer Res."},{"key":"61910_CR27","first-page":"2674","volume":"5","author":"SS Chang","year":"1999","unstructured":"Chang, S. S. et al. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin. Cancer Res. 5, 2674\u20132681 (1999).","journal-title":"Clin. Cancer Res."},{"key":"61910_CR28","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s00259-013-2374-2","volume":"40","author":"M Eder","year":"2013","unstructured":"Eder, M., Eisenhut, M., Babich, J. & Haberkorn, U. PSMA as a target for radiolabelled small molecules. Eur. J. Nucl. Med. Mol. Imaging. 40, 819\u2013823 (2013).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging."},{"key":"61910_CR29","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00259-014-2949-6","volume":"42","author":"A Afshar-Oromieh","year":"2015","unstructured":"Afshar-Oromieh, A. et al. The diagnostic value of PET\/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur. J. Nucl. Med. Mol. Imaging. 42, 197\u2013209 (2015).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging."},{"key":"61910_CR30","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s00259-012-2298-2","volume":"40","author":"A Afshar-Oromieh","year":"2013","unstructured":"Afshar-Oromieh, A. et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur. J. Nucl. Med. Mol. Imaging. 40, 486\u2013495 (2013).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging."},{"key":"61910_CR31","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00259-013-2525-5","volume":"41","author":"A Afshar-Oromieh","year":"2014","unstructured":"Afshar-Oromieh, A. et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET\/CT for the diagnosis of recurrent prostate cancer. Eur. J. Nucl. Med. Mol. Imaging. 41, 11\u201320 (2014).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging."},{"key":"61910_CR32","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2174\/1568026619666190201100739","volume":"19","author":"JZ Diao Wei","year":"2019","unstructured":"Diao Wei, J. Z. Liao Xinyang. Recent Advances in Prostate-Specific Membrane Antigen-Based Radiopharmaceuticals. Curr. Top. Med. Chem. 19, 33\u201356 (2019).","journal-title":"Curr. Top. Med. Chem."},{"key":"61910_CR33","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1021\/bc200279b","volume":"23","author":"M Eder","year":"2012","unstructured":"Eder, M. et al. (68)Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 23, 688\u2013697 (2012).","journal-title":"Bioconjug Chem."},{"key":"61910_CR34","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/jlcr.1024","volume":"49","author":"D Le Bars","year":"2006","unstructured":"Le Bars, D., Malleval, M., Bonnefoi, F. & Tourvieille, C. Simple synthesis of [1-11C]acetate. J. Label. Compd. Radiopharm. 49, 263\u2013267 (2006).","journal-title":"J. Label. Compd. Radiopharm."},{"key":"61910_CR35","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/0020-708X(82)90003-5","volume":"33","author":"VW Pike","year":"1982","unstructured":"Pike, V. W., Eakins, M. N., Allan, R. M. & Selwyn, A. P. Preparation of [1\u221211C]acetate\u2014An agent for the study of myocardial metabolism by positron emission tomography. Int. J. Appl. Radiat. Isot. 33, 505\u2013512 (1982).","journal-title":"Int. J. Appl. Radiat. Isot."},{"key":"61910_CR36","doi-asserted-by":"publisher","first-page":"3476","DOI":"10.7150\/thno.31970","volume":"9","author":"E Lindstr\u00f6m","year":"2019","unstructured":"Lindstr\u00f6m, E. et al. Regularized reconstruction of digital time-of-flight (68)Ga-PSMA-11 PET\/CT for the detection of recurrent disease in prostate cancer patients. Theranostics. 9, 3476\u20133484 (2019).","journal-title":"Theranostics."},{"key":"61910_CR37","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1007\/s00259-016-3366-9","volume":"43","author":"D Pfister","year":"2016","unstructured":"Pfister, D. et al. Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with 68Ga-PSMA-HBED-CC than with 18F-Fluoroethylcholine PET\/CT. Eur. J. Nucl. Med. Mol. Imaging. 43, 1410\u20131417 (2016).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging."},{"key":"61910_CR38","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s00259-016-3490-6","volume":"44","author":"J Schwenck","year":"2017","unstructured":"Schwenck, J. et al. Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET\/CT. Eur. J. Nucl. Med. Mol. Imaging. 44, 92\u2013101 (2017).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging."},{"key":"61910_CR39","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/S1470-2045(19)30415-2","volume":"20","author":"J Calais","year":"2019","unstructured":"Calais, J. et al. 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol. 20, 1286\u20131294 (2019).","journal-title":"Lancet Oncol."},{"key":"61910_CR40","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/bju.13202","volume":"118","author":"G Daouacher","year":"2015","unstructured":"Daouacher, G. et al. Laparoscopic extended pelvic lymph node (LN) dissection as validation of the performance of [11C]-acetate positron emission tomography\/computer tomography in the detection of LN metastasis in intermediate- and high-risk prostate cancer. BJU Int. 118, 77\u201383 (2015).","journal-title":"BJU Int."},{"key":"61910_CR41","doi-asserted-by":"publisher","first-page":"90","DOI":"10.2478\/raon-2018-0001","volume":"52","author":"C von Below","year":"2018","unstructured":"von Below, C. et al. MRI and (11)C Acetate PET\/CT for Prediction of Regional Lymph Node Metastasis in Newly Diagnosed Prostate Cancer. Radiol. Oncol. 52, 90\u201397 (2018).","journal-title":"Radiol. Oncol."},{"key":"61910_CR42","doi-asserted-by":"publisher","first-page":"668","DOI":"10.2967\/jnumed.115.154153","volume":"56","author":"M Eiber","year":"2015","unstructured":"Eiber, M. et al. Evaluation of Hybrid 68Ga-PSMA Ligand PET\/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. J. Nuc Med. 56, 668\u2013674 (2015).","journal-title":"J. Nuc Med."},{"key":"61910_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1756287218815793","volume":"11","author":"M Moghul","year":"2019","unstructured":"Moghul, M. et al. Detection rates of recurrent prostate cancer: (68)Gallium (Ga)-labelled prostate-specific membrane antigen versus choline PET\/CT scans. A systematic review. Ther. Adv. Urol. 11, 1\u201310 (2019).","journal-title":"Ther. Adv. Urol."},{"key":"61910_CR44","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","volume":"5","author":"WP Fendler","year":"2019","unstructured":"Fendler, W. P. et al. Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. JAMA Oncol. 5, 856\u2013863 (2019).","journal-title":"JAMA Oncol."},{"key":"61910_CR45","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.eururo.2019.06.030","volume":"76","author":"A Paschalis","year":"2019","unstructured":"Paschalis, A. et al. Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer. Eur. Urol. 76, 469\u2013478 (2019).","journal-title":"Eur. Urol."},{"key":"61910_CR46","doi-asserted-by":"publisher","first-page":"e4308","DOI":"10.1097\/MD.0000000000004308","volume":"95","author":"J Farnebo","year":"2016","unstructured":"Farnebo, J. et al. Progression-free and overall survival in metastatic castration-resistant prostate cancer treated with abiraterone acetate can be predicted with serial C11-acetate PET\/CT. Med. 95, e4308\u2013e4308 (2016).","journal-title":"Med."},{"key":"61910_CR47","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1007\/s00259-017-3887-x","volume":"45","author":"AK Seitz","year":"2018","unstructured":"Seitz, A. K. et al. Preliminary results on response assessment using 68Ga-HBED-CC-PSMA PET\/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy. Eur. J. Nucl. Med. Mol. Imaging. 45, 602\u2013612 (2018).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-61910-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-61910-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-61910-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T08:12:35Z","timestamp":1670314355000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-61910-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,19]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["61910"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-61910-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,19]]},"assertion":[{"value":"24 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest. The study was presented at the EANM annual conference, 2019.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4993"}}